Research Article
Formulation and Optimization of Monolithic Fixed-Dose Combination of Metformin HCl and Glibenclamide Orodispersible Tablets
Table 1
Composition of the preliminary fixed-dose combination of orodispersible tablets.
| | Code | Ingredients (mg) | Compression force (kN) | | MET | GLB | PEG 6000 | CPV | Aspartame | SLS | CSD | Mg.st | MCC |
| | Fp1 | 250 | 2.5 | 7 | 7 | 1.75 | 3.5 | 1 | 3.5 | 73.75 | 5 | | Fp2 | 250 | 2.5 | 24.5 | 7 | 1.75 | 3.5 | 1 | 3.5 | 56.25 | 5 | | Fp3 | 250 | 2.5 | 7 | 35 | 1.75 | 3.5 | 1 | 3.5 | 45.75 | 5 | | Fp4 | 250 | 2.5 | 24.5 | 35 | 1.75 | 3.5 | 1 | 3.5 | 28.25 | 5 | | Fp5 | 250 | 2.5 | 7 | 7 | 1.75 | 3.5 | 1 | 3.5 | 73.75 | 15 | | Fp6 | 250 | 2.5 | 24.5 | 7 | 1.75 | 3.5 | 1 | 3.5 | 56.25 | 15 | | Fp7 | 250 | 2.5 | 7 | 35 | 1.75 | 3.5 | 1 | 3.5 | 45.75 | 15 | | Fp8 | 250 | 2.5 | 24.5 | 35 | 1.75 | 3.5 | 1 | 3.5 | 28.25 | 15 |
|
|
Fp: preliminary formulation; CPV: crospovidone; CSD: colloidal silicon dioxide; Mg.st: magnesium stearate; MCC: microcrystalline cellulose.
|
